Clinical Trials Logo

Clinical Trial Summary

We aim to (1) evaluate the effectiveness of cognitive therapy and paroxetine and their combination, (2) investigate the patterns of change and the mechanisms of action involved during treatment by using psycho-physiological assessments in order to delineate some of the cognitive, behavioural and physiological mechanisms in the patients' response to CT, to paroxetine and placebo.One hundred patients with a primary diagnosis of social phobia will be selected and randomised into four treatment conditions. The first group (N=25) will be treated with CT alone, the second group (N=25) with CT plus paroxetine, the third group (N=25) with paroxetine and clinical management (TAU), the fourth group will receive placebo and clinical management (N=25). All patients will have 12 weeks of treatment in the acute phase, which includes 12 sessions of individual treatment for the two first groups. The 2nd and 3rd groups will in addition have 12 weeks of drug treatment in the maintenance phase. The 4th group will have placebo for 24 weeks and clinical management. The patients will be assessed at pre-treatment, at 12 weeks and at the end of treatment of the acute phase (12 weeks) and by the end of maintenance phase (24 weeks). Follow-up will be at 6 and 12 months.

Measures are based on all three main sources; self-report inventories, clinical assessments by independent raters and psycho-physiological assessments.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT00184106
Study type Interventional
Source Norwegian University of Science and Technology
Contact
Status Completed
Phase Phase 4
Start date October 2004
Completion date December 2010

See also
  Status Clinical Trial Phase
Completed NCT01963806 - ACT-smart: Smartphone-supplemented iCBT for Social Phobia and/or Panic Disorder N/A
Completed NCT00121069 - Study of Escitalopram in the Treatment of Specific Phobia Phase 2/Phase 3
Recruiting NCT03653923 - Neurophysiological Correlates of Exposition Therapy in Spider Phobia N/A
Completed NCT00051220 - Treatment for Specific Phobias in Children Phase 1/Phase 2
Completed NCT02387047 - Validity of a Self-administered Questionnaire to Screen Phobia of Falling in the Elderly N/A
Completed NCT02310152 - Explanatory Clinical Trial of a Novel Parent Intervention for Childhood Anxiety (SPACE) N/A
Completed NCT00000370 - Treatment of Social Phobia N/A
Completed NCT03012035 - The Role of Treatment Expectation in Exposure Training With Spider Fearful Participants N/A
Completed NCT02007694 - Noradrenergic Manipulation and Virtual Reality Exposure Therapy in Phobic Participants Phase 2/Phase 3
Active, not recruiting NCT03188575 - Effectiveness & Cost-effectiveness of Internet-delivered Interventions for Depression and Anxiety Disorders in IAPT N/A
Completed NCT02432703 - A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder Phase 2
Terminated NCT01574014 - Glucocorticoid Treatment for Social Phobia Phase 2
Completed NCT00734422 - Facilitation of Fear Extinction With Yohimbine Hydrochloride in Phobic Participants Phase 2/Phase 3
Not yet recruiting NCT02336802 - Threat-Avoidance Learning in Anxiety Patients N/A
Completed NCT01361074 - In Vivo Versus Augmented Reality Exposure for Small Animal Phobia N/A
Completed NCT00104195 - A Research Study of How Teens With and Without an Anxiety Disorder Make Decisions Phase 1
Completed NCT00035412 - St. John's Wort Versus Placebo in Social Phobia Phase 2
Completed NCT00128401 - Use of an Antibiotic as an Enhancer for the Treatment of Social Phobia Phase 2
Recruiting NCT02020824 - Virtual Reality and Concept of Control in the Treatment of Acrophobia N/A
Terminated NCT01623583 - Effect of Including Synera® in Discussions on Dialysis Access Conversion in Patients With Needle Phobias Phase 4